Cargando…
Time to reconsider CD33 single nucleotide polymorphism in the response to gemtuzumab ozogamicin
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Fondazione Ferrata Storti
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8561291/ https://www.ncbi.nlm.nih.gov/pubmed/34092060 http://dx.doi.org/10.3324/haematol.2021.279043 |
| _version_ | 1784593090354348032 |
|---|---|
| author | Lamba, Jatinder K. Meshinchi, Soheil |
| author_facet | Lamba, Jatinder K. Meshinchi, Soheil |
| author_sort | Lamba, Jatinder K. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8561291 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Fondazione Ferrata Storti |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-85612912021-11-10 Time to reconsider CD33 single nucleotide polymorphism in the response to gemtuzumab ozogamicin Lamba, Jatinder K. Meshinchi, Soheil Haematologica Editorials Fondazione Ferrata Storti 2021-11-01 /pmc/articles/PMC8561291/ /pubmed/34092060 http://dx.doi.org/10.3324/haematol.2021.279043 Text en Copyright© 2021 Ferrata Storti Foundation https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
| spellingShingle | Editorials Lamba, Jatinder K. Meshinchi, Soheil Time to reconsider CD33 single nucleotide polymorphism in the response to gemtuzumab ozogamicin |
| title | Time to reconsider CD33 single nucleotide polymorphism in the response to gemtuzumab ozogamicin |
| title_full | Time to reconsider CD33 single nucleotide polymorphism in the response to gemtuzumab ozogamicin |
| title_fullStr | Time to reconsider CD33 single nucleotide polymorphism in the response to gemtuzumab ozogamicin |
| title_full_unstemmed | Time to reconsider CD33 single nucleotide polymorphism in the response to gemtuzumab ozogamicin |
| title_short | Time to reconsider CD33 single nucleotide polymorphism in the response to gemtuzumab ozogamicin |
| title_sort | time to reconsider cd33 single nucleotide polymorphism in the response to gemtuzumab ozogamicin |
| topic | Editorials |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8561291/ https://www.ncbi.nlm.nih.gov/pubmed/34092060 http://dx.doi.org/10.3324/haematol.2021.279043 |
| work_keys_str_mv | AT lambajatinderk timetoreconsidercd33singlenucleotidepolymorphismintheresponsetogemtuzumabozogamicin AT meshinchisoheil timetoreconsidercd33singlenucleotidepolymorphismintheresponsetogemtuzumabozogamicin |